Literature DB >> 6582916

Response to continuous irradiation (CI) in relation to the initial slope of the cell survival curve for tumours and bone marrow.

T C Stephens, J H Peacock, W U Shipley, G G Steel.   

Abstract

In vivo ultra low dose rate continuous irradiation (CI, 15 cGy h-1) was used in an attempt to accurately quantify low dose radiation response (less than 2 Gy) of both tumour and normal tissue, a parameter which is clinically relevant but difficult to assess using conventional acute radiation survival curves. Dorsally placed tumours were irradiated by housing tumour bearing mice for up to three weeks in a dedicated 137Cs unit taking care to shield the lower body. Response to CI was monitored by an excision cell survival assay. For bone marrow treatment whole body irradiation was used and BM-CFUc were assessed. In all 4 tissues studied (Lewis lung carcinoma, B16 melanoma, carcinoma MT and C57B1/6 bone marrow) cell survival decreased exponentially with dose; the three tumours had similar D0 (approximately 6 Gy), bone marrow was more sensitive (D0 1.5 Gy). Acute in vitro radiation survival curves were analysed using both the multi-target plus single hit and the linear quadratic models of radiation cell kill. Comparison of CI results with acute radiation survival curve parameters derived from each model suggest that CI offers a useful means of assessing the low dose radiosensitivity of tumours and may therefore be useful in the prediction of tumour response to clinically relevant fractionated treatments.

Entities:  

Mesh:

Year:  1984        PMID: 6582916      PMCID: PMC2149133     

Source DB:  PubMed          Journal:  Br J Cancer Suppl        ISSN: 0306-9443


  9 in total

1.  The kinetics of x-ray survival of mammalian cells in vitro.

Authors:  M A BENDER; P C GOOCH
Journal:  Int J Radiat Biol Relat Stud Phys Chem Med       Date:  1962-05

2.  Interpretation of survival-curve data for Chinese hamster cells, line V-79 using the multi-target, multi-target with initial slope, and alpha, beta equations.

Authors:  B C Millar; E M Fielden; J L Millar
Journal:  Int J Radiat Biol Relat Stud Phys Chem Med       Date:  1978-06

3.  A molecular theory of cell survival.

Authors:  K H Chadwick; H P Leenhouts
Journal:  Phys Med Biol       Date:  1973-01       Impact factor: 3.609

4.  The effect of erythrocytes on mouse bone marrow colony development in vitro.

Authors:  T R Bradley; P A Telfer; P Fry
Journal:  Blood       Date:  1971-09       Impact factor: 22.113

5.  Dose-rate effects in mammalian cells. IV. Repairable and nonrepairable damage in noncycling C3H 10T 1/2 cells.

Authors:  R L Wells; J S Bedford
Journal:  Radiat Res       Date:  1983-04       Impact factor: 2.841

6.  Pitfalls in the use of in vitro survival curves for the determination of tumour cell survival with fractionated doses.

Authors:  L Zeitz; J M McDonald
Journal:  Br J Radiol       Date:  1978-08       Impact factor: 3.039

7.  Inherent cellular radiosensitivity as a basic concept for human tumor radiotherapy.

Authors:  B Fertil; E P Malaise
Journal:  Int J Radiat Oncol Biol Phys       Date:  1981-05       Impact factor: 7.038

8.  Influence of in vitro assay conditions on the assessment of radiobiological parameters of the MT tumour.

Authors:  T C Stephens; J H Peacock; P W Sheldon
Journal:  Br J Radiol       Date:  1980-12       Impact factor: 3.039

9.  A soft agar colony assay for Lewis lung tumour and B16 melanoma taken directly from the mouse.

Authors:  V D Courtenay
Journal:  Br J Cancer       Date:  1976-07       Impact factor: 7.640

  9 in total
  2 in total

Review 1.  Preclinical animal research on therapy dosimetry with dual isotopes.

Authors:  Mark W Konijnenberg; Marion de Jong
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-04-01       Impact factor: 9.236

2.  A Model for Estimating Dose-Rate Effects on Cell-Killing of Human Melanoma after Boron Neutron Capture Therapy.

Authors:  Yusuke Matsuya; Hisanori Fukunaga; Motoko Omura; Hiroyuki Date
Journal:  Cells       Date:  2020-04-30       Impact factor: 6.600

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.